HRX215 is an inhibitor of MAP kinase kinase 4 (MKK4, IC50 = 0. µM). It is selective for MKK4 over JNK1, B-RAF, and MKK7 (IC50s = 7. 11. and 14. µM, respectively). HRX215 (10 mg/kg) decreases hepatocyte apoptosis in a mouse model of liver damage induced by carbon tetrachloride (CCl4). It increases survival and...

Description: Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Target: Antiviral, MAPK. Smiles:...